Genetic Suppressor Elements Proving Useful in Drug Resistance Research

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 3
Volume 5
Issue 3

SEATTLE--Researchers at the University of Illinois at Chicago are using novel approaches to identify and analyze the genes involved in making cancer cells more resistant, or more sensitive, to chemotherapy agents, Igor Roninson, PhD, head of the Molecular Oncology Division, said at a symposium held in conjunction with the American Society of Hematology annual meeting.

SEATTLE--Researchers at the University of Illinois at Chicagoare using novel approaches to identify and analyze the genes involvedin making cancer cells more resistant, or more sensitive, to chemotherapyagents, Igor Roninson, PhD, head of the Molecular Oncology Division,said at a symposium held in conjunction with the American Societyof Hematology annual meeting.

Inhibitors of several signal transduction pathways can preventinduction of the multidrug-resistance gene (MDR-1) in drug-treatedcells, Dr. Roninson said, and MDR-1 is only one of many genesinvolved in determining the cellular response to chemotherapeutictreatment.

His laboratory has developed a new approach to the analysis ofthese genes, using genetic suppressor elements (GSEs). GSEs areshort gene fragments that counteract the gene from which theyare derived, by encoding dominant negative peptides or efficientantisense RNAs.

GSEs can be isolated from recombinant retroviral libraries bylooking for improved survival or enhanced cell death in transducedcells exposed to a particular drug. This allows the team to analyzethe specific mechanisms of resistance.

Another advantage of this approach is that it can uncover clinicallyrelevant resistance mechanisms that do not occur in drug-resistantcell lines, because these lines have been artificially selectedby gradually increasing drug levels.

Since GSEs can potentially inactivate particular genes or theirprotein products, they may prove useful as chemosen-sitizing agents.By introducing a GSE for the BCL2 apoptosis suppressor into leukemiaand breast cancer cell lines, Dr. Roninson increased sensitivityto chemo-therapy by a full order of magnitude.

Recent Videos
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
2 experts are featured in this series.
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
2 experts are featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
Related Content